KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

KORU Medical Systems, Inc. (NASDAQ: KRMD), a prominent player in the medical technology sector, is poised to reveal its financial performance for the fourth quarter and full year of 2025 on March 12, 2026. This announcement underscores the company's commitment to transparency and provides stakeholders with insights into its financial health and strategic direction. KORU Medical has scheduled a conference call and webcast for 4:30 p.m. ET on the day of the announcement, where management will discuss the results and provide a corporate update.

The company specializes in developing, manufacturing, and commercializing large-volume subcutaneous infusion solutions that focus on enhancing patient experiences. Its flagship offering, the Freedom Syringe Infusion System, includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, alongside Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. Since receiving FDA clearance in 1994, the Freedom System has been pivotal for both self-administration by patients at home and professional use in ambulatory infusion centers.

In addition to its core products, KORU Medical's Novel Therapies business segment caters to biopharmaceutical companies, providing tailored solutions for clinical trials during drug development. This adaptability showcases KORU Medical's commitment to innovation and collaboration within the healthcare sector.

Investors interested in the upcoming financial results can join the conference call by accessing it via designated phone lines, or tune into the live and archived webcast available on the company’s website, which will remain accessible for six months. For further details, stakeholders can contact Louisa Smith at KORU Medical's investor relations.

For more information about KORU Medical, visit their official website at www.korumedical.com.

As KORU Medical Systems, Inc. (NASDAQ: KRMD) prepares to release its fourth quarter and full year 2025 financial results on March 12, 2026, investors should approach the upcoming earnings call with a keen understanding of the company's key market drivers and potential implications for its stock performance.

KORU Medical stands at a pivotal intersection within the healthcare landscape, specializing in innovative large volume subcutaneous infusion solutions. With the company's Freedom Syringe Infusion System being integral to both patient self-administration and healthcare professional-assisted delivery, market expansion opportunities abound. Positive performance in this sector is not just contingent on product efficacy, but also on the increasing focus on patient-centric care, which aligns well with current healthcare trends.

Analysts should scrutinize the upcoming earnings report for indicators of revenue growth, particularly in the Novel Therapies business, which caters to biopharmaceutical companies. The demand for customized infusion solutions in drug development may bode well for future revenue, especially if KORU can leverage partnerships or collaborations that amplify its reach within this niche.

Investors should also keep an eye on costs and margins, as profitability metrics will be crucial in gauging the impact of any recent operational enhancements or new technological advancements. Furthermore, guidance provided during the earnings call may reveal management's outlook for 2026 and beyond, providing critical insight into the company's growth trajectory.

Given the competitive and regular updates in the medical technology field, maintaining a close watch on the company's future product pipelines and regulatory developments will be vital. The March 12 conference call and webcast will be instrumental in shaping investor sentiment around KORU Medical. As always, investors should take a balanced view, weighing both potential growth opportunities and inherent risks before making investment decisions.